Inivata Announces Collaboration with F-star Therapeutics for the use of RaDaRTM Assay
May 25, 2021 07:00 ET
|
Inivata
Inivata Announces Collaboration with F-star Therapeutics for the use of RaDaRTM Assay RaDaR ctDNA liquid biopsy to monitor response of late-stage solid tumors to treatment Research Triangle Park,...
Inivata to be Acquired by NeoGenomics
May 05, 2021 07:00 ET
|
Inivata
Inivata to be Acquired by NeoGenomics Exercise of purchase option to acquire remaining Inivata equity interest for $390m Inivata to become a liquid biopsy focused division of NeoGenomics Research...
Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer
April 28, 2021 07:00 ET
|
Inivata
Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer Agendia granted co-exclusive distribution rights for RaDaR in North America and Europe ...
Inivata Presents New Data in Support of its Liquid Biopsy Technologies at AACR Virtual Annual Meeting 2021
April 10, 2021 08:30 ET
|
Inivata
Inivata Presents New Data in Support of its Liquid Biopsy Technologies at AACR Virtual Annual Meeting 2021 Inivata’s RaDaR® MRD assay performed with exceptionally high sensitivity and...
Inivata to Present New Data in Support of its RaDaR™ MRD and InVisionFirst®-Lung tests at AACR Virtual Annual Meeting 2021
March 17, 2021 08:00 ET
|
Inivata
Inivata to Present New Data in Support of its RaDaR™ MRD and InVisionFirst®-Lung tests at AACR Virtual Annual Meeting 2021 Research Triangle Park, NC, USA and Cambridge, UK, 17 March 2021 --...
FDA Grants Breakthrough Device Designation for Inivata’s RaDaR™ Assay
March 09, 2021 07:00 ET
|
Inivata
FDA Grants Breakthrough Device Designation for Inivata’s RaDaR™ Assay Designation will help accelerate the regulatory path of RaDaR for use in detection of MRD in early-stage cancer patients ...
Inivata Raises $35 million in Second Close of Series C Financing
February 04, 2021 07:00 ET
|
Inivata
Inivata Raises $35 million in Second Close of Series C Financing Funds will accelerate clinical development of RaDaR™ minimal residual disease assay and commercialization of InVisionFirst®-Lung ...
First Patients Tested with InVisionFirst®-Lung in EORTC Sponsored Phase II NSCLC Study
January 20, 2021 07:00 ET
|
Inivata
First Patients Tested with InVisionFirst®-Lung in EORTC Sponsored Phase II NSCLC Study Inivata’s InVisionFirst®-Lung is being used for ctDNA testing and monitoring of patients...
Inivata’s Liquid Biopsy Technology Included in Unique £10m Research Collaboration for Early Detection of Lung Cancer
December 18, 2020 07:00 ET
|
Inivata
Inivata’s Liquid Biopsy Technology Included in Unique £10m Research Collaboration for Early Detection of Lung Cancer Research Collaboration to be led by the University of Southampton and along with...
Inivata Appoints Dr. Alan Schafer as Chief Technology Officer
November 16, 2020 07:00 ET
|
Inivata
Inivata Appoints Dr. Alan Schafer as Chief Technology Officer Research Triangle Park, NC, USA and Cambridge, UK, 16 November 2020 – Inivata, a leader in liquid biopsy, today announces the...